Potential of small molecule protein tyrosine kinase inhibitors as immunomodulators and inhibitors of the development of diabetes

TheScientificWorldJournal

Volumn 9, Issue , 2009, Pages 224-228

  Little, Peter J ^a,b   Cohen, Neale ^a   Morahan, Grant ^c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Autoimmunity; Imatinib; NOD mouse; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ABELSON KINASE; CD3 ANTIBODY; IMATINIB; INSULIN; PANCREAS ISLET CELL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SMALL MOLECULE TRANSPORT AGENT; IMMUNOLOGIC FACTOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BLINDNESS; CELL INFILTRATION; DIABETES MELLITUS; ENZYME INHIBITOR INTERACTION; GENETIC SUSCEPTIBILITY; HEART INFARCTION; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY DISEASE; LIMB AMPUTATION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PREVALENCE; STROKE; TREATMENT OUTCOME; VASCULAR DISEASE; ANIMAL; DRUG ANTAGONISM; HUMAN;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; IMMUNOLOGIC FACTORS; MICE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 65649112928     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2009.28     Document Type: Article

References (22)

1. Colman, P.G., Thomas, D.W., Zimmet, P.Z., Welborn, T.A., Garcia-Webb, P., and Moore, M.P. (1999) New classification and criteria for diagnosis of diabetes mellitus. Position Statement from the Australian Diabetes Society, New Zealand Society for the Study of Diabetes, Royal College of Pathologists of Australasia and Australasian Association of Clinical Biochemists. Med. J. Aust. 170, 375-378. (Pubitemid 29192273)
2. Fourlanos, S., Narendran, P., Byrnes, G.B., Colman, P.G., and Harrison, L.C. (2004) Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 47, 1661-1667. (Pubitemid 40022398)
3. Couper, J.J., Beresford, S., Hirte, C., Baghurst, P.A., Pollard, A., Tait, B.D., Harrison, L.C., and Colman, P.G. (2009) Weight gain in early life predicts risk of islet autoimmunity in children with a first-degree relative with type 1 diabetes. Diabetes Care 32, 94-99.
4. Nanto-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipila, J.I., Haavisto, L., Siltala, M., Tuominen, J., Hakalax, J., Hyoty, H., Ilonen, J., Veijola, R., Simell, T., Knip, M., and Simell, O. (2008) Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372, 1746-1755.
5. Herold, K.C., Gitelman, S.E., Masharani, U., Hagopian, W., Bisikirska, B., Donaldson, D., Rother, K., Diamond, B., Harlan, D.M., and Bluestone, J.A. (2005) A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala- Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54, 1763-1769. (Pubitemid 40770766)
6. Hagerkvist, R., Sandler, S., Mokhtari, D., and Welsh, N. (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J. 21, 618-628. (Pubitemid 46213508)
7. Louvet, C., Szot, G.L., Lang, J., Lee, M.R., Martinier, N., Bollag, G., Zhu, S., Weiss, A., and Bluestone, J.A. (2008) Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 105, 18895-18900.
8. Leiter, E.H. (2005) Nonobese diabetic mice and the genetics of diabetes susceptibility. Curr. Diab. Rep. 5, 141-148.
9. Traxler, P., Bold, G., Buchdunger, E., Caravatti, G., Furet, P., Manley, P., O'Reilly, T., Wood, J., and Zimmermann, J. (2001) Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21, 499-512. (Pubitemid 32959239)
10. Wolf, A.M., Wolf, D., Rumpold, H., Ludwiczek, S., Enrich, B., Gastl, G., Weiss, G., and Tilg, H. (2005) The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc. Natl. Acad. Sci. U. S. A. 102, 13622-13627. (Pubitemid 41420898)
11. Paniagua, R.T., Sharpe, O., Ho, P.P., Chan, S.M., Chang, A., Higgins, J.P., Tomooka, B.H., Thomas, F.M., Song, J.J., Goodman, S.B., Lee, D.M., Genovese, M.C., Utz, P.J., Steinman, L., and Robinson, W.H. (2006) Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116, 2633-2642. (Pubitemid 44511627)
12. Veneri, D., Franchini, M., and Bonora, E. (2005) Imatinib and regression of type 2 diabetes. N. Engl. J. Med. 352, 1049-1050.
13. Ballinger, M.L., Osman, N., Wilks, A.F., Su, S., Burns, C.J., Bu, X., and Little, P.J. (2008) Pyrido-pyrimidine derivative CYC10424 inhibits glycosaminoglycan changes on vascular smooth muscle-derived proteoglycans and reduces lipoprotein binding. J. Cardiovasc. Pharmacol. 52, 403-412.
14. Breccia, M., Muscaritoli, M., Aversa, Z., Mandelli, F., and Alimena, G. (2004) Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J. Clin. Oncol. 22, 4653-4655. (Pubitemid 41185138)
15. Dingli, D., Wolf, R.C., and Vella, A. (2007) Imatinib and type 2 diabetes. Endocr. Pract. 13, 126-130.
16. Han, M.S., Chung, K.W., Cheon, H.G., Rhee, S.D., Yoon, C.H., Lee, M.K., Kim, K.W., and Lee, M.S. (2009) Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. Diabetes 58, 329-336.
17. Xu, C., Bailly-Maitre, B., and Reed, J.C. (2005) Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest. 115, 2656-2664. (Pubitemid 41434389)
18. Hagerkvist, R., Jansson, L., and Welsh, N. (2008) Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin. Sci. (Lond.) 114, 65-71.
19. Tsapas, A., Vlachaki, E., Sarigianni, M., Klonizakis, F., and Paletas, K. (2008) Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML). Leuk. Res. 32, 674-675. (Pubitemid 351248965)
20. Billemont, B., Medioni, J., Taillade, L., Helley, D., Meric, J.B., Rixe, O., and Oudard, S. (2008) Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br. J. Cancer 99, 1380-1382.
21. Lassila, M., Allen, T.J., Cao, Z., Thallas, V., Jandeleit-Dahm, K.A., Candido, R., and Cooper, M.E. (2004) Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24(5), 935-942.
22. Wang, S., Wilkes, M.C., Leof, E.B., and Hirschberg, R. (2005) Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J. 19, 1-11. (Pubitemid 40069914)